申请人:Celtaxsys, Inc.
公开号:US10385007B2
公开(公告)日:2019-08-20
This present disclosure is directed to compounds of formula (I):
where r, q, R1a, R1b, R1c, R1d, R1e, R2, R3, R4a, R5a, R5b, R6a, R6b, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
本公开涉及式 (I) 化合物:
其中r、q、R1a、R1b、R1c、R1d、R1e、R2、R3、R4a、R5a、R5b、R6a、R6b、R8和R9为本文所述的单一立体异构体或立体异构体混合物,或其药学上可接受的盐、溶解物、凝胶体、多晶型物、
铵离子、N-氧化物或原药;它们是
白三烯A4
水解酶
抑制剂,因此可用于治疗炎症性疾病。还提供了包括本文所述化合物的药物组合物和制备本文所述化合物的方法。